Preparation of a nanovaccine against Brucella melitensis M16 based on PLGA nanoparticles and oligopolysaccharide antigen

References

• Aparicio ED. Epidemiology of brucellosis in domestic animals caused by Brucella melitensis, Brucella suis and Brucella abortus. Rev Sci Tech Off Int Epiz. 2013;32(1):53–60.
   Google Scholar
• Singh D, Goel D, Bhatnagar R. Recombinant L7/L12 protein entrapping PLGA (poly lactide-co-glycolide) micro particles protect BALB/c mice against the virulent B. abortus 544 infection. Vaccine. 2015;33(24):2786–2792.
   PubMed Web of Science ®Google Scholar
• Alavi SM, Alavi L. Treatment of brucellosis: a systematic review of studies in recent twenty years. Caspian J Int Med. 2013;4(2):636.
   PubMedGoogle Scholar
• Fan Y, Moon JJ. Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens. WIREs Nanomed Nanobiotechnol. 2017;9(1):e1403.
   Web of Science ®Google Scholar
• Cutler SJ, Whatmore AM, Commander NJ. Brucellosis–new aspects of an old disease. J Appl Microbiol. 2005;98(6):1270–1281.
   PubMed Web of Science ®Google Scholar
• Yang X, Skyberg JA, Cao L, et al. Progress in Brucella vaccine development. Front Biol. 2013;8(1):60–77.
   Google Scholar
• McCullers JA, Dunn JD. Advances in vaccine technology and their impact on managed care. P & T. 2008;33(1):35.
   PubMedGoogle Scholar
• Danhier F, Ansorena E, Silva JM, et al. PLGA-based nanoparticles: an overview of biomedical applications. J Contr Rel. 2012;161(2):505–522.
   PubMed Web of Science ®Google Scholar
• Desai MP, Hilfinger JM, Amidon GL, et al. Immune response with biodegradable nanospheres and alum: studies in rabbits using staphylococcal enterotoxin B-toxoid. J Microencaps. 2000;17(2):215–225.
   PubMed Web of Science ®Google Scholar
• Kim MG, Park JY, Shon Y, Kim G, et al. Nanotechnology and vaccine development. Asian J Pharma Sci. 2014;9(5):227–235.
   Google Scholar
• Karch CP, Burkhard P. Vaccine technologies: from whole organisms to rationally designed protein assemblies. Biochem Pharmacol. 2016;120:1–4.
   PubMed Web of Science ®Google Scholar
• Chen L, Li S, Wang Z, et al. Protective effect of recombinant staphylococcal enterotoxin A entrapped in polylactic-co-glycolic acid microspheres against Staphylococcus aureus infection. Vet Res. 2012;43(1):20.
   PubMed Web of Science ®Google Scholar
• Jiang W, Schwendeman SP. Stabilization of tetanus toxoid encapsulated in PLGA microspheres. Mol Pharma. 2008;5(5):808–817.
   PubMed Web of Science ®Google Scholar
• Huang S-S, Li I-H, Hong P-D, et al. Development of Yersinia pestis F1 antigen-loaded microspheres vaccine against plague. Int J Nanomed. 2014; 9:813.
   PubMed Web of Science ®Google Scholar
• Singh D, Somani VK, Aggarwal S, et al. PLGA (85:15) nanoparticle based delivery of rL7/L12 ribosomal protein in mice protects against Brucella abortus 544 infection: a promising alternate to traditional adjuvants. Mol Immunol. 2015;68(2):272–279.
   PubMed Web of Science ®Google Scholar
• Zhu M, Wang R, Nie G. Applications of nanomaterials as vaccine adjuvants. Human Vaccines Immunother. 2014;10(9):2761–2774.
   PubMed Web of Science ®Google Scholar
• Manish M, Rahi A, Kaur M, et al. A single-dose PLGA encapsulated protective antigen domain 4 nanoformulation protects mice against Bacillus anthracis spore challenge. PLoS one. 2013;8(4):e61885.
   PubMed Web of Science ®Google Scholar
• Fairley SJ, Singh SR, Yilma AN, et al. Chlamydia trachomatis recombinant MOMP encapsulated in PLGA nanoparticles triggers primarily T helper 1 cellular and antibody immune responses in mice: a desirable candidate nanovaccine. Int J Nanomed. 2013;8:2085.
   PubMed Web of Science ®Google Scholar
• Alikhani Z, Salouti M, Ardestani MS. Synthesis and immunological evaluation of a nanovaccine based on PLGA nanoparticles and alginate antigen against infections caused by Pseudomonas aeruginosa. Biomed Phys Eng Express. 2018;4(4):045016.
   Web of Science ®Google Scholar
• Dorneles EM, Sriranganathan N, Lage AP. Recent advances in Brucella abortus vaccines. Vet Res. 2015;46(1):76.
   PubMed Web of Science ®Google Scholar
• Bundle DR, McGiven J. Brucellosis: improved diagnostics and vaccine insights from synthetic glycans. Acc Chem Res. 2017;50(12):2958–2967.
   PubMed Web of Science ®Google Scholar
• Cryz SJ, Fürer E, Que JU. Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin A conjugate vaccine. Infect Immun. 1991;59(1):45–50.
   PubMed Web of Science ®Google Scholar
• Oñate AA, Vemulapalli R, Andrews E, et al. Vaccination with live Escherichia coli expressing Brucella abortus Cu/Zn superoxide dismutase protects mice against virulent B. abortus. Infect Immun. 1999;67(2):986–988.
   PubMed Web of Science ®Google Scholar
• Farjah A, Owlia P, Siadat SD, et al. Immunological evaluation of an alginate‐based conjugate as a vaccine candidate against Pseudomonas aeruginosa. APMIS. 2015;123(2):175–183.
   PubMed Web of Science ®Google Scholar
• Weissenböck A, Wirth M, Gabor F. WGA-grafted PLGA-nanospheres: preparation and association with Caco-2 single cells. J Contr Rel. 2004;99(3):383–392.
   PubMed Web of Science ®Google Scholar
• Kumar R, Sahoo GC, Pandey K, et al. Development of PLGA–PEG encapsulated miltefosine based drug delivery system against visceral leishmaniasis. Mater Sci Eng: C. 2016;59:748–753.
   PubMed Web of Science ®Google Scholar
• Sun SB, Liu P, Shao FM, et al. Formulation and evaluation of PLGA nanoparticles loaded capecitabine for prostate cancer. Int J Clin Exper Med. 2015;8(10):19670.
   PubMed Web of Science ®Google Scholar
• Zaidi TS, Priebe GP, Pier GB. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection. Infect Immun. 2006;74(2):975–983.
   PubMed Web of Science ®Google Scholar
• Díaz AG, Quinteros DA, Llabot JM, et al. Spray dried microspheres based on chitosan: a promising new carrier for intranasal administration of polymeric antigen BLSOmp31 for prevention of ovine brucellosis. Mater Sci Eng: C. 2016;62:489–496.
   PubMed Web of Science ®Google Scholar
• Verdolin BA, Ficker SM, Faria AM, et al. Stabilization of serum antibody responses triggered by initial mucosal contact with the antigen independently of oral tolerance induction. Braz J Med Biol Res. 2001;34(2):211–219.
   PubMed Web of Science ®Google Scholar
• Kashef N, Behzadian-Nejad Q, Najar-Peerayeh S, et al. Synthesis and characterization of Pseudomonas aeruginosa alginate–tetanus toxoid conjugate. J Med Microbiol. 2006;55(10):1441–1446.
   PubMed Web of Science ®Google Scholar
• Hufnagel M, Koch S, Kropec A, et al. Opsonophagocytic assay as a potentially useful tool for assessing safety of enterococcal preparations. Int J Food Microbiol. 2003;88(2–3):263–267.
   PubMed Web of Science ®Google Scholar
• Hu BT, Yu X, Jones TR, et al. Approach to validating an opsonophagocytic assay for Streptococcus pneumoniae. Clin Diagn Lab Immunol. 2005;12(2):287–295.
   PubMedGoogle Scholar
• Al-Mariri A, Tibor A, Mertens P, et al. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infect Immun. 2001;69(8):4816–4822.
   PubMed Web of Science ®Google Scholar
• Delpino MV, Estein SM, Fossati CA, et al. Vaccination with Brucella recombinant DnaK and SurA proteins induces protection against Brucella abortus infection in BALB/c mice. Vaccine. 2007;25(37–38):6721–6729.
   PubMed Web of Science ®Google Scholar
• Al-Mariri A. Protection of BALB/c mice against Brucella melitensis 16 M infection induced by vaccination with live Escherchia coli expression Brucella P39 protein. Vaccine. 2010;28(7):1766–1770.
   PubMed Web of Science ®Google Scholar